Biological evaluation of the radioiodinated imidazo[1,2-a]pyridine derivative DRK092 for amyloid-β imaging in mouse model of Alzheimer's disease
Biological evaluation of the radioiodinated imidazo[1,2-a]pyridine derivative DRK092 for amyloid-β imaging in mouse model of Alzheimer's disease
复制标题
DOI:
10.1016/j.neulet.2014.08.036
复制
发表时间:
2014-10-03
影响因子:
2.5
通讯作者:
Ji, Bin
中科院分区:
文献类型:
--
作者:
Chen, Chun-Jen;Bando, Kazunori;Ji, Bin
Non-invasive determination of amyloid-beta peptide (A beta) deposition has important significance for early diagnosis and medical intervention in Alzheimer's disease (AD). In this study, we investigated the availability of a radioiodinated imidazo[1,2-a]pyridine derivative, termed I-125-DRK092, as single photon emission computed tomography (SPECT) ligand for in vivo detection of A beta deposition. DRK092 showed high binding affinity for either synthetic human A beta fibrils or brain homogenates from amyloid precursor protein transgenic (Tg) mouse (PS1-ki/JU-Tg2576) and AD patient with a dissociation constant (K-d) of one-digit nM, and excellent brain permeability (peak value of uptake: approximately 0.9% of injection dose/g rat brain). Ex vivo autoradiographic analysis showed that measurement with I-125-DRK092 has higher sensibility for detecting A beta accumulation than with I-125-IMPY, a well-known amyloid SPECT ligand, in Tg mice. In vitro autoradiography with I-125-DRK092 also confirmed higher accumulation of radioactivity in the cortical area, enriched with A beta plaques, of Tg mouse and AD patient brains, as compared with the corresponding areas in non-Tg mouse and healthy control brains. All the data presented above lead us to draw the conclusion that radioiodinated DRK092 is a potential SPECT ligand for amyloid imaging in AD. (C) 2014 Elsevier Ireland Ltd. All rights reserved.